Apyx Medical Holds 2026 Revenue Forecast

The company kept its $59 million to $60 million revenue outlook while narrowing its operating expense target.

Updated on Nov. 7, 2026 in Healthcare

A stainless steel surgical energy device and coiled cable rest on a pale clinical tray in a clean light-industrial workspace. — Apyx Medical kept its 2026 revenue forecast at $59 million to $60 million while narrowing its operating expense target to $41 million to $42.5 million. AI Illustration. Upload story photo >

Apyx Medical Corporation held its 2026 revenue forecast at $59 million to $60 million and lowered its operating expense target to $41 million to $42.5 million. The company reported third-quarter revenue of $14 million, up 9% year over year.

Why it matters

The narrower cost range signals tighter expense control at the Nasdaq-listed medical device company while its revenue outlook stays flat. Growth in Surgical Aesthetics offset a steep decline in original-equipment-manufacturer sales.

Surgical Aesthetics revenue rose 17% to $13 million in the third quarter, while original-equipment-manufacturer revenue fell 42% to about $1.1 million. The 2026 forecast includes $54 million to $55 million from Surgical Aesthetics and about $5 million from original-equipment-manufacturer sales.

The players

Apyx Medical Corporation

Apyx Medical Corporation is a medical technology company listed on the Nasdaq that develops energy-based surgical and aesthetic devices.

The details

Quarterly operating expenses rose to $9.6 million from $9.1 million, and net loss attributable to stockholders narrowed to $1.8 million from $2 million. Apyx expects gross margins of 63% to 65% for the year.

Full-year 2025 revenue totaled $52.8 million.
Third-quarter results were reported for the three months ended Sept. 30.
The 2026 revenue forecast of $59 million to $60 million was held unchanged.

Market Landscape

Apyx's flat revenue outlook of $59 million to $60 million follows its 2025 full-year revenue of $52.8 million, implying modest growth from that base. The company's reliance on Surgical Aesthetics, which is forecast at $54 million to $55 million for 2026, shows where its growth is concentrated within the company's own portfolio.

For investors holding Apyx shares, the company's unchanged revenue outlook and narrower expense range define the near-term financial picture for 2026. Gross margin guidance of 63% to 65% is the key metric to track in future quarterly reports.

The takeaway

Apyx is holding its revenue line steady while tightening cost expectations, so the coming quarters will show whether Surgical Aesthetics growth can keep carrying the business. Watch gross margin performance against the 63% to 65% target.